Advertisement

Topics

Patricia Nash Company Profile

04:54 EST 17th December 2018 | BioPortfolio

The quintessential embodiment of style, form and function, Patricia Nash Designs creates handbags and accessories that are made of beautiful, vegetable tanned Italian leather. The company was founded in 2012 by the designer Patricia Nash who was inspired by her extensive international travels and vintage handbags found in her mother’s closet. The collection pays homage to Old World craftsmanship through delicate, hand-finished detailing including hand-dying, hand-cutting, hand-sewing and a hand-embossed logo in every design. Patricia Nash Designs is based in Knoxville, TN, and sold in major retail department stores nationwide.


News Articles [311 Associated News Articles listed on BioPortfolio]

Continental Who's Who recognizes Patricia L. Collins, MBA

BUFFALO, N.Y., Sept. 12, 2018 /PRNewswire/ -- Continental Who's Who recognizes Patricia L. Collins, MBA, as a Pinnacle Lifetime Member in the field of Real Read more...

Is NASH Really a $35 Billion Opportunity?

Is NASH Really a $35 Billion Opportunity? And could it be the middle of the pack that wins the prize? For the last few years, investors have been talking up the huge potential of drugs to treat nonalc...

Patricia Blake named new CEO of Heart Rhythm Society

Patricia V. Blake will take over as CEO of the Heart Rhythm Society (HRS) next March, HRS leadership announced Oct. 26.

Drs. Jonathan and Kenneth Nash Treat Gum Disease in Vicksburg, MS with Modern Laser Dentistry, Honor National Gum Care Month

VICKSBURG, MS (PRWEB) September 13, 2018 Nash Family Dentistry team, Drs. Jonathan Nash and Kenneth Nash, are honoring National Gum ...

Genentech buys NASH biotech Jecure

Roche’s Genentech unit has bought California biotech Jecure Therapeutics, which is researching drugs that could be used in inflammatory diseases including the fatty liver disease NASH. Non-alcoholi...

Novartis, Pfizer Partner for NASH

A complex condition with no available treatment options, NASH affects up to 6.5% of the population worldwide

New partners for NASH

This year’s AASLD Liver meeting contains data on new NASH mechanisms for pharmas to consider picking up, but little clarity on combination strategy.

NASH Cirrhosis: The Real NASH Epidemic

PubMed Articles [126 Associated PubMed Articles listed on BioPortfolio]

Treatment of NASH with Gastric Bypass.

Nonalcoholic steatohepatitis (NASH) is a spectrum of nonalcoholic fatty liver disease (NAFLD). It is defined as the presence of fatty liver along with inflammation and hepatocyte injury. To date, weig...

Burden of Illness and Economic Model for Patients with Non-Alcoholic Steatohepatitis (NASH) in the United States.

Non-alcoholic steatohepatitis (NASH) is the progressive form of non-alcoholic fatty liver disease (NAFLD). Our aim was to estimate the total economic burden of NASH and advanced NASH in the United Sta...

The future R&D landscape in non-alcoholic steatohepatitis (NASH).

Nonalcoholic steatohepatitis (NASH) is emerging as a major public health issue for the 21st century and is associated with significant liver-related morbidity and mortality. At present, there are no a...

Long-term effect of bariatric surgery on resolution of nonalcoholic steatohepatitis (NASH): An external validation and application of a clinical NASH score.

Nonalcoholic steatohepatitis (NASH) is an important etiology of end-stage liver disease. Long-term effect of bariatric surgery in improvement of NASH is not clear.

Gemcabene downregulates inflammatory, lipid-altering and cell-signaling genes in the STAM™ model of NASH.

Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) can advance, if untreated, to liver fibrosis, cirrhosis, hepatocellular carcinoma, liver failure and liver-related de...

Clinical Trials [169 Associated Clinical Trials listed on BioPortfolio]

Phase 1 Pharmacokinetic Study Of CP-945598 In Patients With NASH

CP-945598 is a potent and selective Cannabinoid-1 (CB1) receptor antagonist currently being developed for the treatment of obesity. CP-945598 is also being considered as a potential treat...

Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH

The primary objective of this study is the proof of mechanism and support of dose finding, together with the safety evaluation in patients with clinical evidence of NASH. To gain further ...

A 5-year Longitudinal Observational Study of Patients With Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH)

TARGET-NASH is a longitudinal observational cohort study of patients being managed for NAFLD or NASH in usual clinical practice. TARGET-NASH will create a research registry of patients wit...

Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH

The purpose of the present study is to assess the effects of LMB763 with respect to safety, tolerability, and on markers of liver inflammation in patients with NASH

Bariatric Embolization of Arteries for the Treatment of Nonalcoholic Steatohepatitis (BEAT-NASH)

Obesity is an epidemic in the US. With progression of obesity, Nonalcoholic steatohepatitis (NASH) has been a growing public health issue. Presently there is no cure for NASH.Prevention of...

Companies [41 Associated Companies listed on BioPortfolio]

Patricia Nash

The quintessential embodiment of style, form and function, Patricia Nash Designs creates handbags and accessories that are made of beautiful, vegetable tanned Italian leather. The...

Nash Finch Company

North American Specialty Hospital

Headquartered in Denver, NASH is a US majority-owned and managed enterprise. Incorporating US physicians in its service delivery, NASH is designed to provide pre-operative and pos...

HARVEY NASH GROUP

Harvey Nash was founded in London in 1988. David Higgins, the current Executive Vice Chairman, was one of the original founders and still has a sizeable financial stake in the company. Early on, the m...

Jecure Therapeutics Inc.

Jecure Therapeutics is focused on the discovery of novel therapeutics for the treatment of NASH and liver fibrosis. Jecure’s scientific founder is Dr. Ariel Feldstein, Divisi...

More Information about "Patricia Nash" on BioPortfolio

We have published hundreds of Patricia Nash news stories on BioPortfolio along with dozens of Patricia Nash Clinical Trials and PubMed Articles about Patricia Nash for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Patricia Nash Companies in our database. You can also find out about relevant Patricia Nash Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record